PNPLA3 and metabolic dysfunction-associated steatotic liver disease: For instance, variations in the prevalence of genetic polymorphisms such as PNPLA3 and TM6SF2, both strongly associated with NAFLD susceptibility and progression in Chinese populations, may impact the effectiveness of GSH treatment [113,114,115,116].